Oppenheimer Remains a Buy on Prestige Consumer Healthcare (PBH)
In a report released yesterday, Rupesh Parikh from Oppenheimer maintained a Buy rating on Prestige Consumer Healthcare. The company’s shares closed yesterday at $64.70.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Parikh covers the Consumer Defensive sector, focusing on stocks such as Church & Dwight, Costco, and Walmart. According to TipRanks, Parikh has an average return of 11.6% and a 63.02% success rate on recommended stocks.
Prestige Consumer Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $77.00.
Based on Prestige Consumer Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $274.11 million and a net profit of $42.21 million. In comparison, last year the company earned a revenue of $283.55 million and had a net profit of $54.38 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PBH in relation to earlier this year. Last month, Jeffrey Zerillo, the SVP Operations of PBH sold 1,000.00 shares for a total of $60,000.00.
